The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort

BACKGROUND AND AIM: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). MATERIALS AND METHODS: Between May 2019 and May 2022, 686 patients with CHC, treated with GL...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaras, Serkan, Demir, Mehmet, Barutcu, Sezgin, Yildirim, Abdullah Emre, Gurel, Selim, Ucbilek, Enver, Kurtulmus, Ilkce Akgun, Kayhan, Meral Akdogan, Vatansever, Sezgin, Adanir, Haydar, Danis, Nilay, Duman, Serkan, Turan, Ilker, Ari, Derya, Kose, Sukran, Alkim, Huseyin, Harputluoglu, Muhsin Murat, Dilber, Feyza, Akyildiz, Murat, Cosar, Arif Mansur, Durak, Serdar, Sirin, Goktug, Kefeli, Ayse, Gokcan, Hale, Avcioglu, Ufuk, Ayyildiz, Talat, Sezgin, Orhan, Akarsu, Mesut, Dincer, Dinc, Guzelbulut, Fatih, Gunsar, Fulya, Akarca, Ulus Salih, Idilman, Ramazan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564251/
https://www.ncbi.nlm.nih.gov/pubmed/37822314
http://dx.doi.org/10.14744/hf.2023.2023.0001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564251/
https://www.ncbi.nlm.nih.gov/pubmed/37822314
http://dx.doi.org/10.14744/hf.2023.2023.0001

Ejemplares similares